dipyridamole has been researched along with Fra(X) Syndrome in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nadazdin, A | 1 |
| Shahi, M | 1 |
| Foale, RA | 1 |
1 other study available for dipyridamole and Fra(X) Syndrome
| Article | Year |
|---|---|
Impaired left ventricular filling during ST-segment depression provoked by dipyridamole infusion in patients with syndrome X.
Topics: Aged; Angina Pectoris; Chest Pain; Coronary Angiography; Coronary Disease; Dipyridamole; Echocardiog | 1991 |